Home › Companies › Amphastar Pharmaceuticals, Inc. › 2025-2026

Amphastar Pharmaceuticals, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Amphastar Pharmaceuticals, Inc.’s Form 8-K, filed 2026-06-03 (Item 5.07 on EDGAR). Page generated 02 October 2026.

8Reported items
262Asset managers
2,197Fund votes
2026-06-01Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Amphastar Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Amphastar Pharmaceuticals, Inc.

These tallies are Amphastar Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-03 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Amphastar Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2026-06-01
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: David Gaugh	35,242,863	209,084	25,045	--	4,439,978	Majority: yes
Elect Director: William J. Peters	23,652,131	11,785,772	39,089	--	4,439,978	Majority: yes
Elect Director: Jacob Liawatidewi	23,224,791	12,212,988	39,213	--	4,439,978	Majority: yes

Source: Amphastar Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2026-06-03 — read the filing on EDGAR.

How asset managers voted at the Amphastar Pharmaceuticals, Inc. 2025-2026 meeting

Each item below shows how the 262 asset managers that disclosed a Amphastar Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Amphastar Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

87% fund support · no official result

FOR 87%13%

The 254 asset managers below cast 87% of the shares they voted on this item FOR (22,439,631 for, 3,449,805 against).

FOR: 22,439,631 (86.6%)AGAINST: 3,449,805 (13.3%)ABSTAIN: 32,030 (0.1%)NOT VOTED: 271 (0.0%)

Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers.” at Amphastar Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	4,495,622	9,518	For
Vanguard	2,712,856	9	For
American Century	0	2,010,450	Against
State Street	1,458,266	7,924	For
FULLER & THALER ASSET MANAGEMENT, INC.	1,390,971	0	For
Capitol Series Trust	1,336,827	0	For
GEODE CAPITAL MANAGEMENT, LLC	966,560	0	For
Epoch Investment Partners, Inc.	899,431	0	For
Fidelity	859,342	0	For
Dimensional	857,357	0	For
Charles Schwab	614,920	0	For
Invesco	454,457	0	For
BOSTON TRUST WALDEN NATIONAL ASSOCIATION	0	437,740	Against
Victory Capital	430,355	0	For
Royce	407,620	0	For
BOSTON TRUST WALDEN FUNDS	0	381,171	Against
LSV ASSET MANAGEMENT	282,055	2,100	For
Northern Trust	264,953	3,960	For
Pacer Funds Trust	260,598	0	For
BESSEMER INVESTMENT MANAGEMENT LLC	241,494	0	For
SYSTEMATIC FINANCIAL MANAGEMENT LP	212,737	17,850	For
PRINCIPAL GLOBAL INVESTORS	209,539	0	For
MELLON INVESTMENTS Corp	188,415	0	For
World Funds Trust	175,516	0	For
EA Series Trust	153,614	0	For

Showing the 25 largest of 254 asset managers. See all 254 in the interactive database.

2. To approve, on an advisory basis, the frequency of future stockholder advisory votes on our named executive officer compensation.

SECTION 14A SAY-ON-PAY VOTES

Combines 2 wordings of this item as funds reported it.

98% fund support · no official result

ONE YEAR 66%1 YEAR 30%

The 253 asset managers below cast 98% of the shares they voted on this item FOR (72,556 for, 1,114 against).

FOR: 72,556 (0.3%)AGAINST: 1,114 (0.0%)ABSTAIN: 24,030 (0.1%)ONE YEAR: 17,146,449 (66.2%)1 YEAR: 7,778,331 (30.0%)THREE YEARS: 869,387 (3.4%)3 YEARS: 14,419 (0.1%)1: 8,000 (0.0%)NOT VOTED: 425 (0.0%)1.0: 176 (0.0%)3.0: 8 (0.0%)

Largest asset managers voting on “To approve, on an advisory basis, the frequency of future stockholder advisory votes on our named executive of” at Amphastar Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
BlackRock	0	0	0	0	1 Year
Vanguard	0	0	0	0	One Year
American Century	0	0	0	0	One Year
State Street	0	0	0	0	One Year
FULLER & THALER ASSET MANAGEMENT, INC.	0	0	0	0	One Year
Capitol Series Trust	0	0	0	0	One Year
GEODE CAPITAL MANAGEMENT, LLC	0	0	0	0	One Year
Epoch Investment Partners, Inc.	0	0	0	0	One Year
Fidelity	0	0	0	0	One Year
Dimensional	0	0	0	0	Three Years
Charles Schwab	0	0	0	0	1 Year
Invesco	0	0	0	0	One Year
BOSTON TRUST WALDEN NATIONAL ASSOCIATION	0	0	0	0	One Year
Victory Capital	0	0	0	0	One Year
Royce	0	0	0	0	One Year
BOSTON TRUST WALDEN FUNDS	0	0	0	0	One Year
LSV ASSET MANAGEMENT	0	0	0	0	1 Year
Northern Trust	0	0	0	0	1 Year
Pacer Funds Trust	0	0	0	0	1 Year
BESSEMER INVESTMENT MANAGEMENT LLC	0	0	0	0	One Year
SYSTEMATIC FINANCIAL MANAGEMENT LP	0	0	0	0	1 Year
PRINCIPAL GLOBAL INVESTORS	0	0	0	0	One Year
MELLON INVESTMENTS Corp	0	0	0	0	One Year
World Funds Trust	0	0	0	0	1 Year
EA Series Trust	0	0	0	0	1 Year

Showing the 25 largest of 253 asset managers. See all 253 in the interactive database.

3. To elect three Class I directors to serve until the Company's 2029 annual meeting of stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: David Gaugh

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%

FOR: 35,242,863AGAINST: 209,084

Amphastar Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: David Gaugh”): 35,242,863 for, 209,084 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 44,636,846 outstanding shares: 79% for, 0.5% against (79% of the company cast a for/against vote).

The 80 asset managers below cast 99.9% of the shares they voted on this item FOR (14,165,044 for, 6,096 against).

FOR 99.8%

FOR: 14,165,044 (99.9%)AGAINST: 6,096 (0.0%)ABSTAIN: 13,430 (0.1%)

Largest asset managers voting on “To elect three Class I directors to serve until the Company's 2029 annual meeting of stockholders and until ea” at Amphastar Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	3,391,723	0	For
Vanguard	2,396,788	1	For
Capitol Series Trust	1,336,827	0	For
American Century	988,729	0	For
Fidelity	858,264	0	For
State Street	762,919	0	For
Dimensional	672,444	0	For
Royce	398,860	0	For
BOSTON TRUST WALDEN FUNDS	381,171	0	For
Charles Schwab	293,617	0	For
Pacer Funds Trust	260,598	0	For
Invesco	208,048	0	For
Victory Capital	179,178	0	For
World Funds Trust	175,516	0	For
EA Series Trust	153,614	0	For
First Trust	149,869	0	For
OLD WESTBURY FUNDS INC	120,747	0	For
BRIDGEWAY FUNDS INC	85,694	0	For
Equitable	82,675	0	For
TIAA	75,172	0	For
EXCHANGE TRADED CONCEPTS TRUST	70,551	0	For
AMERICAN BEACON FUNDS	68,300	0	For
Jackson National	63,835	0	For
Transamerica	63,700	0	For
ADVISORS' INNER CIRCLE FUND	62,154	0	For

Showing the 25 largest of 80 asset managers. See all 80 in the interactive database.

4. To elect three Class I directors to serve until the Company's 2029 annual meeting of stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: Jacob Liawatidewi

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

66% Majority: yes · of votes cast

FOR 66%AGAINST 34%

FOR: 23,224,791AGAINST: 12,212,988

Amphastar Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: Jacob Liawatidewi”): 23,224,791 for, 12,212,988 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 44,636,846 outstanding shares: 52.0% for, 27% against (79% of the company cast a for/against vote).

The 80 asset managers below cast 55% of the shares they voted on this item FOR (7,819,667 for, 6,351,473 against).

FOR 55%AGAINST 45%

FOR: 7,819,667 (55.1%)AGAINST: 6,351,473 (44.8%)ABSTAIN: 13,430 (0.1%)

Largest asset managers voting on “To elect three Class I directors to serve until the Company's 2029 annual meeting of stockholders and until ea” at Amphastar Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	3,391,723	0	For
Vanguard	2,390,899	5,890	For
Capitol Series Trust	0	1,336,827	Against
American Century	0	988,729	Against
Fidelity	857,164	1,100	For
State Street	1,518	761,401	Against
Dimensional	0	672,444	Against
Royce	0	398,860	Against
BOSTON TRUST WALDEN FUNDS	0	381,171	Against
Charles Schwab	0	293,617	Against
Pacer Funds Trust	260,598	0	For
Invesco	208,048	0	For
Victory Capital	0	179,178	Against
World Funds Trust	175,516	0	For
EA Series Trust	7,017	146,597	Against
First Trust	0	149,869	Against
OLD WESTBURY FUNDS INC	0	120,747	Against
BRIDGEWAY FUNDS INC	0	85,694	Against
Equitable	52,975	29,700	For
TIAA	75,172	0	For
EXCHANGE TRADED CONCEPTS TRUST	0	70,551	Against
AMERICAN BEACON FUNDS	0	68,300	Against
Jackson National	0	63,835	Against
Transamerica	0	63,700	Against
ADVISORS' INNER CIRCLE FUND	0	62,154	Against

Showing the 25 largest of 80 asset managers. See all 80 in the interactive database.

5. To elect three Class I directors to serve until the Company's 2029 annual meeting of stockholders and until each such director's successor is elected and qualified or until such director's earlier death, resignation or removal: William J. Peters

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

67% Majority: yes · of votes cast

FOR 67%AGAINST 33%

FOR: 23,652,131AGAINST: 11,785,772

Amphastar Pharmaceuticals, Inc.’s own tally for this item (“Elect Director: William J. Peters”): 23,652,131 for, 11,785,772 against, per its Form 8-K filed 2026-06-03 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 44,636,846 outstanding shares: 53.0% for, 26% against (79% of the company cast a for/against vote).

The 80 asset managers below cast 57% of the shares they voted on this item FOR (8,139,524 for, 6,031,616 against).

FOR 57%AGAINST 43%

FOR: 8,139,524 (57.4%)AGAINST: 6,031,616 (42.5%)ABSTAIN: 13,430 (0.1%)

Largest asset managers voting on “To elect three Class I directors to serve until the Company's 2029 annual meeting of stockholders and until ea” at Amphastar Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	3,391,723	0	For
Vanguard	2,390,903	5,886	For
Capitol Series Trust	0	1,336,827	Against
American Century	0	988,729	Against
Fidelity	857,164	1,100	For
State Street	1,518	761,401	Against
Dimensional	0	672,444	Against
Royce	0	398,860	Against
BOSTON TRUST WALDEN FUNDS	0	381,171	Against
Charles Schwab	293,617	0	For
Pacer Funds Trust	260,598	0	For
Invesco	208,048	0	For
Victory Capital	0	179,178	Against
World Funds Trust	175,516	0	For
EA Series Trust	7,017	146,597	Against
First Trust	0	149,869	Against
OLD WESTBURY FUNDS INC	0	120,747	Against
BRIDGEWAY FUNDS INC	0	85,694	Against
Equitable	82,675	0	For
TIAA	75,172	0	For
EXCHANGE TRADED CONCEPTS TRUST	0	70,551	Against
AMERICAN BEACON FUNDS	0	68,300	Against
Jackson National	0	63,835	Against
Transamerica	0	63,700	Against
ADVISORS' INNER CIRCLE FUND	0	62,154	Against

Showing the 25 largest of 80 asset managers. See all 80 in the interactive database.

6. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2026; and

AUDIT-RELATED

Combines 2 wordings of this item as funds reported it.

99% fund support · no official result

FOR 99%

The 79 asset managers below cast 99% of the shares they voted on this item FOR (13,968,719 for, 175,709 against).

FOR: 13,968,719 (98.7%)AGAINST: 175,709 (1.2%)ABSTAIN: 13,430 (0.1%)

Largest asset managers voting on “To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm ” at Amphastar Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	3,391,723	0	For
Vanguard	2,390,956	5,833	For
Capitol Series Trust	1,336,827	0	For
American Century	988,729	0	For
Fidelity	858,264	0	For
State Street	762,843	76	For
Dimensional	672,444	0	For
Royce	398,860	0	For
BOSTON TRUST WALDEN FUNDS	381,171	0	For
Charles Schwab	293,617	0	For
Pacer Funds Trust	260,598	0	For
Invesco	208,048	0	For
Victory Capital	179,178	0	For
World Funds Trust	175,516	0	For
EA Series Trust	7,017	146,597	Against
First Trust	149,869	0	For
OLD WESTBURY FUNDS INC	120,747	0	For
BRIDGEWAY FUNDS INC	85,694	0	For
Equitable	82,675	0	For
TIAA	75,172	0	For
EXCHANGE TRADED CONCEPTS TRUST	70,551	0	For
AMERICAN BEACON FUNDS	68,300	0	For
Jackson National	63,835	0	For
Transamerica	63,700	0	For
ADVISORS' INNER CIRCLE FUND	62,154	0	For

Showing the 25 largest of 79 asset managers. See all 79 in the interactive database.

7. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 71%ONE YEAR 29%

The 3 asset managers below cast 100% of the shares they voted on this item FOR (123,824 for, 0 against).

FOR: 123,824 (70.7%)ONE YEAR: 51,217 (29.3%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at Amphastar Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Vote
NORDEA INVESTMENT MANAGEMENT AB	123,824	For
Empower	0	One Year
ADVISORY RESEARCH INC	0	One Year

8. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

29% fund support · no official result

FOR 29%AGAINST 71%

The 3 asset managers below cast 29% of the shares they voted on this item FOR (51,217 for, 123,824 against).

FOR: 51,217 (29.3%)AGAINST: 123,824 (70.7%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at Amphastar Pharmaceuticals, Inc., 2025-2026
Asset manager	For	Against	Vote
NORDEA INVESTMENT MANAGEMENT AB	0	123,824	Against
Empower	26,712	0	For
ADVISORY RESEARCH INC	24,505	0	For

Largest Amphastar Pharmaceuticals, Inc. shareholders voting in 2025-2026

Ranked by the number of Amphastar Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 44,636,846 shares outstanding at the time of that meeting.

Top Amphastar Pharmaceuticals, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	BlackRock	10.09%
2	Vanguard	6.08%
3	American Century	4.50%
4	State Street	3.28%
5	FULLER & THALER ASSET MANAGEMENT, INC.	3.12%
6	Capitol Series Trust	2.99%
7	GEODE CAPITAL MANAGEMENT, LLC	2.17%
8	Epoch Investment Partners, Inc.	2.01%
9	Fidelity	1.93%
10	Dimensional	1.92%

Reported Amphastar Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Amphastar Pharmaceuticals, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Jack Y. Zhang	27.83%	DEF14A
Mary Z. Luo	27.83%	DEF14A
Applied Physics & Chemistry Laboratories, Inc.	15.30%	DEF14A
BlackRock	12.15%	13F
Vanguard Group	5.84%	13F
Dimensional Fund Advisors	4.54%	13F
State Street	3.60%	13F
Geode Capital	2.19%	13F
D.E. Shaw	1.49%	13F
Invesco	1.35%	13F

Percentages above are of 44,636,846 shares outstanding, as reported by Amphastar Pharmaceuticals, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Amphastar Pharmaceuticals, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Amphastar Pharmaceuticals, Inc.'s shareholder meeting held 2026-06-01, in the 2025-2026 proxy season, 262 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,197 separate fund positions. Their filings are grouped here into 8 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. Amphastar Pharmaceuticals, Inc.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on an advisory basis, the compensation of the Company's named executive officers. — the reporting funds cast 87% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

Amphastar Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).